Good morning, everyone, and welcome to another working week, which is an abbreviated affair on this side of the pond after an extended holiday weekend. We hope the respite was refreshing and relaxing, since this is also a signal that summer has essentially ended. And that can mean only one thing: quaffing cups of stimulation. Our choice today is cinnamon vanilla nut. Please feel free to join us. Meanwhile, here are some tidbits to help you ease in. Hope you have a smashing day and, of course, do stay in touch. We enjoy your notes and tips …
Stamford, Conn., which is home to Purdue Pharma, has so far not signaled plans to join other Connecticut cities suing the drug maker over the opioid crisis, The Advocate reports. Five Connecticut towns have so far pledged to join the legal fray and another 15 to 20 are likely to follow, according to Waterbury Mayor Neil O’Leary. Purdue, which sells OxyContin, paid $3 million in taxes last year.
About the Author Reprints
A clinical trial does not require a drug a priori. If it is exploratory it’s end product will be a publication, and for that voluteers need to sign an informed consent saying how their data may wind up. Doubtless these studies will involve some kind of technology, such as neuroimaging, and for that you need consent.